Author: anna_acnr

Briumvi beats Aubagio as first MS treatment in ULTIMATE trial analysis

Briumvi led to fewer relapses, less MRI activity and better disability improvement than Aubagio when used as the first disease-modifying therapy for relapsing multiple sclerosis, according to a new post-hoc analysis of the phase 3 ULTIMATE I and II trials.

The analysis focused on 722 participants who had not previously received an approved disease-modifying therapy, including 279 people whose first MS symptoms had appeared within three years of entering the trials. Researchers found that starting treatment with Briumvi, also known as ublituximab, produced better outcomes than Aubagio, teriflunomide, across several key measures after 96 weeks.

In the treatment-naive group, Briumvi reduced the annualised relapse rate by 56.7% compared with Aubagio, with relapse rates of 0.081 versus 0.188. In the subgroup treated earlier in the disease course, within three years of symptom onset, the reduction was 61.0%, with relapse rates of 0.130 versus 0.334.

The study also found higher rates of confirmed disability improvement with Briumvi. In the overall treatment-naive population, 10.7% of patients receiving Briumvi achieved 12-week confirmed disability improvement compared with 5.3% of those on Aubagio. In the early-treatment subgroup, the gap was wider, 14.4% versus 3.6%. Rates of confirmed disability progression were low in both arms and did not differ significantly.

| Sign up to the ACNR email newsletter here |

MRI outcomes also favoured Briumvi. Compared with Aubagio, the therapy reduced gadolinium-enhancing T1 lesions by 96.1% in the treatment-naive population and 95.0% in the early-treatment subgroup. New or enlarging T2 lesions were cut by 90.6% and 91.6% respectively.

A further measure, no evidence of disease activity, was achieved by 82.7% of treatment-naive patients on Briumvi compared with 23.1% on Aubagio. In the early-treatment subgroup, the rates were 80.5% and 23.8%.

The researchers said the findings add to evidence supporting early use of high-efficacy therapies in relapsing MS, but noted that the analysis was retrospective and based on a relatively small subgroup. They said prospective head-to-head trials are still needed to compare high-efficacy treatments started early in the disease course.

This news item has been summarised using AI and checked by humans before publication


Sources

GlobalNewswire

Frontiers in Immunology

| Sign up for our online community for neurology specialists |

Women with Parkinson’s may have more Alzheimer’s-related brain changes than men, study suggests

Women with Parkinson’s disease may be more likely than men to show Alzheimer’s-related changes in the brain, according to research presented at the European Academy of Neurology Congress 2026.

The study, led by researchers at Mayo Clinic Arizona, examined 230 autopsy-confirmed cases of Parkinson’s disease from the Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. Participants underwent annual clinical assessments during life and detailed neuropathological examinations after death, allowing researchers to compare Alzheimer’s-related brain pathology between men and women with Parkinson’s disease.

The researchers found that women had significantly greater amyloid plaque burden than men. Amyloid plaques are a hallmark feature of Alzheimer’s disease and are thought to play an important role in neurodegeneration. Female participants had higher average cortical plaque scores and greater neuritic plaque density than male participants. More than half of the women in the study had a high plaque burden, compared with just under 40% of men.

The association remained significant even after adjusting for age at death and APOE ε4, a well-established genetic risk factor for Alzheimer’s disease. Overall, women with Parkinson’s disease were more than twice as likely as men to have a high amyloid plaque burden.

Despite these pathological differences, the study did not identify significant sex differences in rates of Alzheimer’s dementia or performance on cognitive testing. Men and women with Parkinson’s disease showed similar cognitive outcomes during life, even though women had more extensive Alzheimer’s-related brain changes at post-mortem examination.

The researchers said this disconnect between brain pathology and clinical symptoms raises important questions. It may reflect the complexity of the relationship between amyloid burden and cognitive decline, or it may indicate that larger studies are needed to detect subtle differences in cognition over time.

| Sign up to the ACNR email newsletter here |

The findings add to growing evidence that women may be biologically more vulnerable to Alzheimer’s-related pathology, including in the context of Parkinson’s disease. The team said further large clinicopathological studies are needed to confirm the results and to explore the mechanisms behind these sex differences, which could eventually help shape more tailored approaches to diagnosis and care.

This news item has been summarised using AI and checked by humans before publication


Sources

European Academy of Neurology Congress 2026

| Sign up for our online community for neurology specialists |

Multiple sclerosis affects social life and work as much as physical health, study finds

Multiple sclerosis can affect far more than a person’s physical health, with new research suggesting that social life, employment, finances and education are all commonly disrupted by the condition.

The findings were presented at the European Academy of Neurology Congress 2026 and come from the SocialMS study, a nationwide Italian survey involving 1,039 adults with multiple sclerosis receiving care at 68 specialist centres. Researchers examined how the disease affected four social determinants of health: education, work, financial resources and social life.

Impact of multiple sclerosis (MS) on social determinants of health (SDH). Left panel:
Frequency of participants reporting impact of MS in the four domains. Numbers on
connecting lines indicate participants reporting impact in both domains. Right panel:
Distribution of participants according to the number of domains impacted by MS (0–4).

Social life was the area most often affected, with 51% of participants reporting an impact. Work was close behind at 48%, followed by financial resources at 34% and education at 19%. The researchers also found that these areas were closely linked, particularly work and social life, and work and finances, suggesting that difficulties in one part of life may worsen challenges in another.

The burden was greatest among people who were already more vulnerable. Participants facing financial strain, unemployment or early retirement, additional health conditions or higher levels of disability were more likely to report difficulties across several domains. Disability and economic hardship were associated with all of the study’s secondary outcomes.

Support networks were common, with almost 90% of participants saying they received some form of help. Family members were the main source of both practical and emotional support, while friends also played an important emotional role. Some participants also reported receiving support from pets and colleagues.

| Sign up to the ACNR email newsletter here |

However, the study highlighted the complexity of these relationships. Among those whose social life had been affected by MS, more than half said it had strained their relationship with a partner, while nearly half reported an impact on friendships.

The researchers said the findings underline the need for more person-centred care that looks beyond physical symptoms alone. They argue that routine assessment of employment, finances, education and social participation, alongside closer coordination between healthcare and social support services, could help identify unmet needs earlier and reduce inequalities for people living with MS.

This news item has been summarised using AI and checked by humans before publication


Sources

European Academy of Neurology Congress 2026

| Sign up for our online community for neurology specialists |

Alixorexton improves wakefulness in narcolepsy type 2 phase 2 study

Alkermes has reported positive detailed results from the phase 2 Vibrance-2 study of alixorexton in adults with narcolepsy type 2, showing significant improvements in wakefulness and excessive daytime sleepiness compared with placebo.

The findings, presented at SLEEP 2026 in Baltimore, mark the first large phase 2 study of an orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant benefits in narcolepsy type 2, a condition in which orexin deficiency is not typically seen. Alixorexton is an investigational once-daily oral selective orexin 2 receptor agonist currently in development for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.

Vibrance-2 was a randomised, double-blind, placebo-controlled dose-ranging trial involving 93 adults with narcolepsy type 2. Participants received alixorexton at doses of 10 mg, 14 mg or 18 mg, or placebo, once daily for eight weeks, followed by a five-week open-label extension.

The drug met both dual primary endpoints at week eight. On the Maintenance of Wakefulness Test, alixorexton improved mean sleep latency compared with placebo across all doses, with statistically significant effects at 14 mg and 18 mg. Participants had a baseline mean sleep latency of around six minutes, rising to approximately 14 to 16 minutes at week eight depending on dose.

Alixorexton also improved excessive daytime sleepiness as measured by the Epworth Sleepiness Scale, with clinically meaningful benefits across all doses and statistical significance at the 18 mg dose. By week 13, mean Epworth scores across all dose groups were within the normal range.

| Sign up to the ACNR email newsletter here |

Exploratory patient-reported outcomes suggested additional benefits for fatigue and cognition. Improvements in fatigue and cognitive complaints emerged as early as week two and were sustained through week 13.

Alixorexton was generally well tolerated across all doses, with no serious treatment-emergent adverse events reported. The most common adverse events included pollakiuria, insomnia, urinary urgency, dizziness and headache. More than 95% of participants completed the double-blind phase.

Alkermes has already launched a global phase 3 programme in narcolepsy type 1 and type 2. If confirmed in larger trials, alixorexton could become an important new treatment option for central disorders of hypersomnolence.

This news item has been summarised using AI and checked by humans before publication.


Sources

Alkermes

SLEEP 2026

| Sign up for our online community for neurology specialists |

13-second eye test may help predict recovery of consciousness after severe brain injury

A 13-second bedside eye test could help clinicians predict whether patients with severe brain injuries are likely to regain consciousness, according to research presented at the European Academy of Neurology Congress 2026 in Geneva.

The findings suggest that a little-studied part of the pupil’s reaction to light, known as the late light-off response, may offer an early sign of recovery potential in people with acute disorders of consciousness. Researchers found that this delayed pupil response predicted improvements in consciousness seven days later, while standard pupil measurements already used in intensive care did not.

The study was led by researchers from Copenhagen University Hospital Rigshospitalet and the Technical University of Denmark. It included 250 patients with impaired consciousness after traumatic and non-traumatic brain injury, as well as 30 healthy controls matched for age and sex. Patients underwent daily automated pupillometry and neurological assessments for up to 20 days while in intensive care.

The late light-off response refers to a later phase of pupil behaviour that occurs after the eye has reacted to light. According to the researchers, this measurement was linked to later improvement even after taking account of baseline neurological status, time since injury, sedation and type of brain injury. Importantly, it was not associated with how responsive patients appeared on the same day, suggesting it may reveal recovery potential not visible during routine bedside checks.

| Sign up to the ACNR email newsletter here |

Lead author Dr Poul Laigaard said current pupil tests show how the brain is functioning at a particular moment, but the late light-off response may provide clues about the brain’s capacity to recover over the following days. The effect appeared strongest in patients who were not receiving sedative medication and in those with anoxic-ischaemic brain injury, although the team stressed that these subgroup findings were exploratory.

Senior author Professor Daniel Kondziella said larger multicentre studies are now needed to confirm whether the method could be used routinely for bedside monitoring and prognosis. Because automated pupillometers are already available in many intensive care units, the researchers believe the test could be relatively straightforward to introduce if future studies support its use.

References

  1. Laigaard, P., Stückler, S., Eigenbrodt, A. et al. (2026). Pupillary light-off latency predicts 7-day improvement in consciousness in patients with acute disorders of consciousness. Abstract A-26-17842. Presented at the 12th EAN Congress (Geneva, Switzerland).
  2. Edlow, B.L., Claassen, J., Schiff, N.D., Greer, D.M. (2021). Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies. Nature Reviews Neurology; 17(3):135–156.
  3. Messina, Z., Shapshak, A.H., Mills, R. (2023). Anoxic Encephalopathy. StatPearls. NCBI. Available at: https://www.ncbi.nlm.nih.gov/books/NBK539833/.

This news item has been summarised using AI and checked by humans before publication.


Sources

European Academy of Neurology (EAN) Congress 2026

| Sign up for our online community for neurology specialists |

Hearing aids linked to lower dementia risk in people with epilepsy

Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to research presented at the European Academy of Neurology (EAN) Congress 2026.

Hearing loss is recognised as the largest modifiable risk factor for dementia, but evidence that hearing aids reduce dementia risk has remained inconsistent. Researchers from University Hospital Zurich and the University of Liverpool investigated whether hearing aids may offer greater benefits in people already at increased risk of dementia because of neurological, metabolic or cardiovascular conditions.

The team analysed electronic health records from more than 250 million patients in the TriNetX network. Adults with hearing loss who used hearing aids were compared with closely matched individuals who did not use hearing aids. The analysis included people with epilepsy, stroke, type 2 diabetes, chronic kidney disease, heart failure, migraine and osteoarthritis.

No significant association was found between hearing aid use and dementia risk in the overall population with hearing loss or among people with stroke, migraine, type 2 diabetes, chronic kidney disease, heart failure or osteoarthritis.

| Sign up to the ACNR email newsletter here |

However, among adults with both epilepsy and hearing loss, hearing aid use was associated with a 23% lower risk of dementia. This equated to an absolute risk reduction of 2.7 percentage points over five years, corresponding to one fewer dementia diagnosis for every 37 people using hearing aids.

Lead author Dr Carolina Ferreira-Atuesta said the finding was unexpected because the researchers had anticipated smaller benefits across several high-risk groups rather than a consistent effect confined to epilepsy. The team believes reduced cognitive reserve in people with epilepsy may make them more vulnerable to the additional cognitive demands imposed by untreated hearing loss.

The researchers suggest hearing assessments could become part of routine epilepsy care, as patients already have regular contact with healthcare services. They also emphasised that treating hearing loss offers well-established benefits for communication, mood and social engagement, regardless of any potential impact on dementia risk.

As the study was observational, it cannot prove that hearing aids directly reduce dementia risk. The researchers say prospective studies are now needed to determine whether hearing intervention can help preserve long-term brain health in people with epilepsy.

References

  1. Ferreira-Atuesta, C., Schubert, K.M., Jung, H. et al. (2026). Hearing Aid Use and Risk of Dementia in Adults with Hearing Loss and Comorbid Neurological, Metabolic, or Cardiovascular Conditions. Abstract A-26-18825. Presented at the 12th EAN Congress (Geneva, Switzerland).
  2. NIHR. Biomedical Research Centre. (2025). Certain chronic health conditions associated increased risk of dementia – new study.
    https://oxfordhealthbrc.nihr.ac.uk/certain-chronic-health-conditions-associated with-increased-risk-of-dementia-new-study/
  3. Alzheimer’s Research UK. (2024). Cognitive reserve and dementia risk. https://www.alzheimersresearchuk.org/dementia-information/dementia
    risk/cognitive-reserve-and-dementia-risk/

This news item has been summarised using AI and checked by humans before publication.


Sources

European Academy of Neurology (EAN) Congress 2026

| Sign up for our online community for neurology specialists |

New study reveals different drivers behind rising numbers of Parkinson’s, multiple sclerosis and motor neuron disease

The growing number of people living with Parkinson’s disease (PD), multiple sclerosis (MS) and motor neuron disease (MND) is being driven by different underlying factors, according to new research due to be presented at the European Academy of Neurology (EAN) Congress 2026 and published in Neurology [1,2].

Researchers from France and Sweden analysed nationwide health data covering the entire populations of both countries to examine trends in the prevalence, incidence and life expectancy of people living with PD, MS and MND between 2003 and 2022. While the number of people living with all three conditions increased, the factors driving these trends differed substantially between diseases.

MS prevalence appears to be increasing largely because people are living longer after diagnosis, likely reflecting advances in treatment and care. In contrast, MND was the only condition to show rising age-adjusted incidence, suggesting factors beyond population ageing may be contributing. For Parkinson’s disease, age-adjusted incidence declined over time, indicating that historical increases in prevalence have been driven mainly by improved survival rather than increasing disease risk.

While crude incidence of PD and MS remained largely stable throughout the study period, both crude and age-adjusted incidence increased for MND. Life expectancy also improved for people living with MS and MND. For PD, life expectancy increased between 2003 and 2013 before declining in later years.

Lead author Dr Thomas Nedelec, from Sorbonne University and the Paris Brain Institute, said, “The fastest-growing disease in terms of prevalence is multiple sclerosis. Importantly, this rise does not appear to be driven by increasing incidence, but by improved life expectancy among patients.”

Discussing the possible reasons behind improved MS survival, Dr Nedelec added, “For multiple sclerosis, advances in immunosuppressive and immunomodulatory therapies may have contributed substantially by reducing disease activity and improving long-term outcomes.”

| Sign up to the ACNR email newsletter here |

For MND, researchers say population ageing explains much of the increase in incidence, but not all of it. Greater awareness and improvements in diagnosis may have contributed to more cases being identified, although the possibility of changing environmental or lifestyle-related risk factors cannot yet be ruled out.

For PD, the picture appears more complex. Once the effects of population ageing were taken into account, the number of new cases declined over time. Researchers suggest this pattern may reflect better disease management and improved treatment of related health conditions, particularly cardiovascular disease.

Dr Nedelec explained, “There are several important messages here. The number of people living with these neurological conditions continues to rise substantially, but this does not appear to be driven by a major increase in new cases. That is reassuring from a public health perspective, as it suggests we are not seeing a dramatic rise in population-level risk.”

The findings highlight the importance of understanding the different mechanisms driving disease prevalence, as rising survival and increasing incidence have very different implications for healthcare planning, service provision and disease prevention.

Looking ahead, the research team are calling for a coordinated European effort to better understand long-term neurological disease trends.

“We see a clear need for a large-scale European initiative that reproduces this type of analysis across the continent,” Dr Nedelec concluded. “This would help us better understand differences between countries and improve our understanding of the factors driving these diseases.”

References

  1. Guinebretière, O., Yang, F., Fang, F., Nedelec, T. (2026). Drivers of Rising Prevalence in Major Motor Neurodegenerative Diseases: Temporal Trends in Sweden and France (2003–2022). Presented at the 12th EAN Congress (Geneva, Switzerland).
  2. GUINEBRETIERE, Octave, YANG, Fen, WEI, Dang, et al. Drivers of rising prevalence in major motor neurodegenerative diseases: temporal trends in Sweden and France (2003–2022). Neurology, 2026, vol. 107, no 1, p. e218072.

Sources

European Academy of Neurology (EAN) Congress 2026

| Sign up for our online community for neurology specialists |

Sarah Tabrizi recognised in King’s Birthday Honours for Huntington’s disease research

Professor Sarah Tabrizi has been appointed a Commander of the Order of the British Empire (CBE) in the 2026 King’s Birthday Honours in recognition of her services to people with Huntington’s disease and her pioneering contributions to neurological research.

Professor Tabrizi is a Group Leader at the UK Dementia Research Institute (UK DRI) at UCL, Director of the UCL Huntington’s Disease Centre and Joint Head of the Department of Neurodegenerative Disease at the UCL Queen Square Institute of Neurology. Over nearly three decades, she has led groundbreaking research that has transformed understanding of Huntington’s disease and helped establish entirely new approaches to treatment.

Her multidisciplinary work combines fundamental laboratory science with clinical research involving patients, generating major insights into the biology and progression of Huntington’s disease. This research has helped redefine the disease from a condition once considered untreatable to one that is increasingly viewed as therapeutically tractable.

Among her most significant recent achievements has been leadership of the early-stage clinical trial of the gene therapy AMT-130. Reported results indicated a 75% slowing of disease progression over 36 months, representing a major advance in the search for effective treatments for Huntington’s disease and providing renewed hope for patients and families affected by the condition.

Responding to the honour, Professor Tabrizi said the recognition reflected the collective efforts of researchers, clinicians and the Huntington’s disease community. She paid tribute to the patients and families who have participated in research programmes, describing their commitment, resilience and courage as the driving force behind scientific progress.

Professor Tabrizi also acknowledged colleagues at the Huntington’s Disease Centre, UCL Queen Square Institute of Neurology, UCLH National Hospital for Neurology and Neurosurgery and the UK DRI, as well as major funding organisations that have supported her work.

| Sign up to the ACNR email newsletter here |

Professor Siddharthan Chandran, Director of the UK DRI, described the honour as richly deserved, praising Professor Tabrizi’s decades of dedication and stating that her research had transformed expectations for what may be possible in Huntington’s disease treatment.

This news item has been summarised using AI and checked by humans before publication.


Sources

University College London

| Sign up for our online community for neurology specialists |

MS relapses remain rare after age 60 whether DMTs are continued or stopped

A long-term study suggests that people with multiple sclerosis (MS) aged over 60 may face a very low risk of relapses regardless of whether they continue taking disease-modifying therapies (DMTs) or discontinue treatment. Researchers found that clinical disease activity remained uncommon in both groups, although MRI scans frequently revealed changes that warrant further investigation.

The research followed 600 people with MS who were older than 60 and had previously received DMT treatment. Participants were treated at Cleveland Clinic MS centres between 2010 and 2016 and were monitored for a median period of 10.5 years. Of the total cohort, 204 continued using DMTs while 396 stopped treatment, typically in their mid-60s.

During follow-up, only 3.3% of participants experienced a relapse after the age of 60. Most of those affected had a single relapse, and only two individuals experienced more than one episode. Statistical analysis showed no significant difference in relapse risk between those who remained on therapy and those who discontinued treatment.

While clinical relapses were uncommon, MRI findings painted a more complex picture. Approximately one-third of patients with available imaging data developed new T2 lesions, indicating ongoing radiological activity. Rates of new lesions were broadly similar between DMT continuers and discontinuers. Researchers said the significance of these MRI changes remains unclear and highlighted the need for additional studies to determine their impact on long-term outcomes.

| Sign up to the ACNR email newsletter here |

The study also examined patient-reported quality of life. The only significant difference observed involved fatigue. Patients who continued DMTs tended to report improvements in fatigue over time, whereas fatigue scores worsened among those who discontinued treatment. However, the investigators noted that DMTs are not generally known to have a strong effect on fatigue, suggesting that other factors may explain the finding.

The researchers concluded that discontinuing DMTs after age 60 appears feasible for some patients, but ongoing monitoring and further research remain essential as the MS population continues to age.

This news item has been summarised using AI and checked by humans before publication.


Sources

Multiple Sclerosis News Today

Sage Journal

| Sign up for our online community for neurology specialists |

Peppermint oil shows potential to lower blood pressure in new study

Researchers at the University of Lancashire have reported that peppermint oil may offer a simple and inexpensive way to reduce mildly elevated blood pressure, following the results of a new clinical study published in PLOS One.

The study found that participants who consumed 100 microlitres of peppermint oil twice daily for 20 days experienced an average reduction of 8.5 mmHg in systolic blood pressure, the upper figure in a blood pressure reading. The findings suggest peppermint oil could provide a well-tolerated intervention for people with pre-hypertension or stage 1 hypertension.

The trial involved 40 adults aged between 18 and 65 years who were randomly assigned to receive either peppermint oil or a peppermint-flavoured placebo. Participants taking the active treatment demonstrated significant reductions in systolic blood pressure, while those receiving the placebo showed no meaningful changes.

In addition to blood pressure measurements, researchers assessed body composition, blood biomarkers, diastolic blood pressure, heart rate, sleep quality and mental wellbeing. The most notable effect was observed in systolic blood pressure reduction among those receiving peppermint oil.

Lead author Dr Jonnie Sinclair, Reader in Sport and Health Sciences at the University of Lancashire, said the findings could have important public health implications. Hypertension remains one of the leading preventable risk factors for cardiovascular disease and premature mortality worldwide, placing a substantial burden on healthcare systems.

| Sign up to the ACNR email newsletter here |

Peppermint contains biologically active compounds including menthol and flavonoids, which are believed to contribute to its physiological effects. The researchers suggest these compounds may play a role in improving vascular function and lowering blood pressure, although further studies will be required to confirm the underlying mechanisms and assess long-term effectiveness.

While larger trials are needed before peppermint oil can be recommended as a routine treatment, the findings highlight the potential of low-cost nutritional interventions as complementary approaches to managing cardiovascular risk.

This news item has been summarised using AI and checked by humans before publication.


Sources

University of Lancashire

PLOS One

| Sign up for our online community for neurology specialists |